CalciMedica Stock (NASDAQ:CALC)
Previous Close
$1.60
52W Range
$1.45 - $6.26
50D Avg
$2.12
200D Avg
$3.38
Market Cap
$20.76M
Avg Vol (3M)
$41.92K
Beta
1.11
Div Yield
-
CALC Company Profile
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.